Central nervous system and brain diseases impact almost 1 billion people per year with approximately 7 million related deaths worldwide. A major challenge to treating these types of diseases is the ability for therapeutics to cross the blood-brain and blood cerebrospinal barriers. These barriers make it extremely difficult to deliver therapies to the brain, which is the primary target for these diseases. Thus, there is an unmet need for novel treatments that can decrease mortality and morbidity of this large disease population. The developed technology consists of a novel bio-adhesive drug scaffold that crosses both barriers via the intranasal route and delivers an attached therapeutic for a wide range of diseases. To enhance this delivery route, a bioactive sequence (peptide or protein) is attached onto a cyclic peptide with properties promoting bio-adhesion. This cyclic peptide adheres to nasal mucosa and is absorbed into the tissue.